Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
5.3 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET ANALYSIS
6 EPIDEMOLOGY
7 PIPELINE ANALYSIS
7.1 PHASE III CANDIDATES
7.2 PHASE II CANDIDATES
7.3 PHASE I CANDIDATES
7.4 OTHERS (PRE-CLINICAL AND RESEARCH)
8 INDUSTRY INSIGHTS
8.1 DEMOGRAPHIC TRENDS
8.2 KEY PRICING STRATEGIES
8.3 KEY PATIENT ENROLLMENT STRATEGIES
8.4 INTERVIEWS WITH MANUFACTURING COMPANIES
8.5 OTHER KOL SNAPSHOTS
9 REGULATORY FRAMWORK
10 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET, BY TYPE
10.1 OVERVIEW
(NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB SEGMENTS)
10.2 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)
10.2.1 SARGRAMOSTIM
10.2.2 MOLGRADEX
10.2.3 OTHERS
10.3 RITUXIMAB
10.4 BRONCHODILATOR
10.4.1 BY TYPE
10.4.1.1. BETA-2 AGONISTS
10.4.1.1.1. SALBUTAMOL
10.4.1.1.2. SALMETEROL
10.4.1.1.3. FORMOTEROL
10.4.1.1.4. VILANTEROL
10.4.1.2. ANTICHOLINERGICS
10.4.1.2.1. IPRATROPIUM
10.4.1.2.2. TIOTROPIUM
10.4.1.3. THEOPHYLLINE
10.4.2 BY MECHANISM
10.4.2.1. LONG ACTING
10.4.2.2. SHORT ACTING
10.5 OTHERS
11 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET, BY DISEASE TYPE
11.1 OVERVIEW
11.2 PRIMARY PULMONARY ALVEOLAR PROTEINOSIS
11.2.1 AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS
11.2.2 HEREDITY PULMONARY ALVEOLAR PROTEINOSIS
11.3 SECONDARY PULMONARY ALVEOLAR PROTEINOSIS
11.4 CONGENITAL PULMONARY ALVEOLAR PROTEINOSIS
12 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 BRANDED
12.2.1 LEUKINE
12.2.2 RIABNI
12.2.3 RITUXAN
12.2.4 RUXIENCE
12.2.5 TRUXIMA
12.2.6 VENTOLIN
12.2.7 AIROMIR
12.3 GENERIC
13 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET, BY MODE OF PURCHASE
13.1 OVERVIEW
13.2 PRESCRIPTION
13.3 OVER THE COUNTER
14 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET, BY GENDER
14.1 OVERVIEW
14.2 MALE
14.2.1 CHILDREN
14.2.2 ADULT
14.2.3 GERIATRIC
14.3 FEMALE
14.3.1 CHILDREN
14.3.2 ADULT
14.3.3 GERIATRIC
15 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLETS
15.2.2 CAPSULES
15.3 PARAENTRAL
15.3.1 SUBCUTANEOUS
15.3.2 INTRAVENOUS
15.4 INHALATION
16 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 CLINICS
16.4 SPECIALITY CLINICS
16.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
16.6 OTHERS
17 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 RETAIL SALES
17.3.1 HOSPITAL PHARMACY
17.3.2 RETAIL PHARMACY
17.3.3 ONLINE PHARMACY
18 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET, BY REGION
GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
18.1 NORTH AMERICA
18.1.1 U.S.
18.1.2 CANADA
18.1.3 MEXICO
18.2 EUROPE
18.2.1 GERMANY
18.2.2 U.K.
18.2.3 ITALY
18.2.4 FRANCE
18.2.5 SPAIN
18.2.6 RUSSIA
18.2.7 SWITZERLAND
18.2.8 TURKEY
18.2.9 BELGIUM
18.2.10 NETHERLANDS
18.2.11 DENMARK
18.2.12 SWEDEN
18.2.13 POLAND
18.2.14 NORWAY
18.2.15 FINLAND
18.2.16 REST OF EUROPE
18.3 ASIA-PACIFIC
18.3.1 JAPAN
18.3.2 CHINA
18.3.3 SOUTH KOREA
18.3.4 INDIA
18.3.5 SINGAPORE
18.3.6 THAILAND
18.3.7 INDONESIA
18.3.8 MALAYSIA
18.3.9 PHILIPPINES
18.3.10 AUSTRALIA
18.3.11 NEW ZEALAND
18.3.12 VIETNAM
18.3.13 TAIWAN
18.3.14 REST OF ASIA-PACIFIC
18.4 SOUTH AMERICA
18.4.1 BRAZIL
18.4.2 ARGENTINA
18.4.3 REST OF SOUTH AMERICA
18.5 MIDDLE EAST AND AFRICA
18.5.1 SOUTH AFRICA
18.5.2 EGYPT
18.5.3 BAHRAIN
18.5.4 UNITED ARAB EMIRATES
18.5.5 KUWAIT
18.5.6 OMAN
18.5.7 QATAR
18.5.8 SAUDI ARABIA
18.5.9 REST OF MIDDLE EAST AND AFRICA
18.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
19 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: GLOBAL
19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
19.3 COMPANY SHARE ANALYSIS: EUROPE
19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19.5 MERGERS & ACQUISITIONS
19.6 NEW PRODUCT DEVELOPMENT & APPROVALS
19.7 EXPANSIONS
19.8 REGULATORY CHANGES
19.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
20 GLOBAL PULMONARY ALVEOLAR PROTEINOSIS DRUG MARKET, COMPANY PROFILE
20.1 SANOFI
20.1.1 COMPANY OVERVIEW
20.1.2 REVENUE ANALYSIS
20.1.3 GEOGRAPHIC PRESENCE
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 SAVARA INC.
20.2.1 COMPANY OVERVIEW
20.2.2 REVENUE ANALYSIS
20.2.3 GEOGRAPHIC PRESENCE
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPEMENTS
20.3 F. HOFFMANN-LA ROCHE AG
20.3.1 COMPANY OVERVIEW
20.3.2 REVENUE ANALYSIS
20.3.3 GEOGRAPHIC PRESENCE
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPEMENTS
20.4 BAYER AG
20.4.1 COMPANY OVERVIEW
20.4.2 REVENUE ANALYSIS
20.4.3 GEOGRAPHIC PRESENCE
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPEMENTS
20.5 ASTRAZENECA
20.5.1 COMPANY OVERVIEW
20.5.2 REVENUE ANALYSIS
20.5.3 GEOGRAPHIC PRESENCE
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPEMENTS
20.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
20.6.1 COMPANY OVERVIEW
20.6.2 REVENUE ANALYSIS
20.6.3 GEOGRAPHIC PRESENCE
20.6.4 PRODUCT PORTFOLIO
20.6.5 RECENT DEVELOPEMENTS
20.7 NOVARTIS AG
20.7.1 COMPANY OVERVIEW
20.7.2 REVENUE ANALYSIS
20.7.3 GEOGRAPHIC PRESENCE
20.7.4 PRODUCT PORTFOLIO
20.7.5 RECENT DEVELOPEMENTS
20.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
20.8.1 COMPANY OVERVIEW
20.8.2 REVENUE ANALYSIS
20.8.3 GEOGRAPHIC PRESENCE
20.8.4 PRODUCT PORTFOLIO
20.8.5 RECENT DEVELOPEMENTS
20.9 GLAXOSMITHKLINE PLC
20.9.1 COMPANY OVERVIEW
20.9.2 REVENUE ANALYSIS
20.9.3 GEOGRAPHIC PRESENCE
20.9.4 PRODUCT PORTFOLIO
20.9.5 RECENT DEVELOPEMENTS
20.1 ZYDUS CADILA
20.10.1 COMPANY OVERVIEW
20.10.2 REVENUE ANALYSIS
20.10.3 GEOGRAPHIC PRESENCE
20.10.4 PRODUCT PORTFOLIO
20.10.5 RECENT DEVELOPEMENTS
20.11 CIPLA INC.
20.11.1 COMPANY OVERVIEW
20.11.2 REVENUE ANALYSIS
20.11.3 GEOGRAPHIC PRESENCE
20.11.4 PRODUCT PORTFOLIO
20.11.5 RECENT DEVELOPEMENTS
20.12 MYLAN N.V.
20.12.1 COMPANY OVERVIEW
20.12.2 REVENUE ANALYSIS
20.12.3 GEOGRAPHIC PRESENCE
20.12.4 PRODUCT PORTFOLIO
20.12.5 RECENT DEVELOPEMENTS
20.13 MERCK & CO., INC.
20.13.1 COMPANY OVERVIEW
20.13.2 REVENUE ANALYSIS
20.13.3 GEOGRAPHIC PRESENCE
20.13.4 PRODUCT PORTFOLIO
20.13.5 RECENT DEVELOPEMENTS
20.14 GLENMARK PHARMACEUTICALS LIMITED
20.14.1 COMPANY OVERVIEW
20.14.2 REVENUE ANALYSIS
20.14.3 GEOGRAPHIC PRESENCE
20.14.4 PRODUCT PORTFOLIO
20.14.5 RECENT DEVELOPEMENTS
20.15 PFIZER INC
20.15.1 COMPANY OVERVIEW
20.15.2 REVENUE ANALYSIS
20.15.3 GEOGRAPHIC PRESENCE
20.15.4 PRODUCT PORTFOLIO
20.15.5 RECENT DEVELOPEMENTS
20.16 VECTURA GROUP PLC
20.16.1 COMPANY OVERVIEW
20.16.2 REVENUE ANALYSIS
20.16.3 GEOGRAPHIC PRESENCE
20.16.4 PRODUCT PORTFOLIO
20.16.5 RECENT DEVELOPEMENTS
20.17 SUN PHARMACEUTICAL INDUSTRIES LTD.
20.17.1 COMPANY OVERVIEW
20.17.2 REVENUE ANALYSIS
20.17.3 GEOGRAPHIC PRESENCE
20.17.4 PRODUCT PORTFOLIO
20.17.5 RECENT DEVELOPEMENTS
20.18 AMNEAL PHARMACEUTICALS LLC.
20.18.1 COMPANY OVERVIEW
20.18.2 REVENUE ANALYSIS
20.18.3 GEOGRAPHIC PRESENCE
20.18.4 PRODUCT PORTFOLIO
20.18.5 RECENT DEVELOPEMENTS
20.19 BEXIMCO PHARMACEUTICALS LTD.
20.19.1 COMPANY OVERVIEW
20.19.2 REVENUE ANALYSIS
20.19.3 GEOGRAPHIC PRESENCE
20.19.4 PRODUCT PORTFOLIO
20.19.5 RECENT DEVELOPEMENTS
20.2 MUNDIPHARMA
20.20.1 COMPANY OVERVIEW
20.20.2 REVENUE ANALYSIS
20.20.3 GEOGRAPHIC PRESENCE
20.20.4 PRODUCT PORTFOLIO
20.20.5 RECENT DEVELOPEMENTS
20.21 INOGEN, INC.
20.21.1 COMPANY OVERVIEW
20.21.2 REVENUE ANALYSIS
20.21.3 GEOGRAPHIC PRESENCE
20.21.4 PRODUCT PORTFOLIO
20.21.5 RECENT DEVELOPMENTS
20.22 HOME OXYGEN COMPANY
20.22.1 COMPANY OVERVIEW
20.22.2 REVENUE ANALYSIS
20.22.3 GEOGRAPHIC PRESENCE
20.22.4 PRODUCT PORTFOLIO
20.22.5 RECENT DEVELOPMENTS
20.23 MEDLINE INDUSTRIES, INC
20.23.1 COMPANY OVERVIEW
20.23.2 REVENUE ANALYSIS
20.23.3 GEOGRAPHIC PRESENCE
20.23.4 PRODUCT PORTFOLIO
20.23.5 RECENT DEVELOPMENTS
20.24 NOVARTIS AG
20.24.1 COMPANY OVERVIEW
20.24.2 REVENUE ANALYSIS
20.24.3 GEOGRAPHIC PRESENCE
20.24.4 PRODUCT PORTFOLIO
20.24.5 RECENT DEVELOPMENTS
20.25 ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A
20.25.1 COMPANY OVERVIEW
20.25.2 REVENUE ANALYSIS
20.25.3 GEOGRAPHIC PRESENCE
20.25.4 PRODUCT PORTFOLIO
20.25.5 RECENT DEVELOPMENTS
20.26 HORIZON THERAPEUTICS PLC
20.26.1 COMPANY OVERVIEW
20.26.2 REVENUE ANALYSIS
20.26.3 GEOGRAPHIC PRESENCE
20.26.4 PRODUCT PORTFOLIO
20.26.5 RECENT DEVELOPMENTS
20.27 DR. REDDY’S LABORATORIES LTD.
20.27.1 COMPANY OVERVIEW
20.27.2 REVENUE ANALYSIS
20.27.3 GEOGRAPHIC PRESENCE
20.27.4 PRODUCT PORTFOLIO
20.27.5 RECENT DEVELOPMENTS
20.28 ABBOTT
20.28.1 COMPANY OVERVIEW
20.28.2 REVENUE ANALYSIS
20.28.3 GEOGRAPHIC PRESENCE
20.28.4 PRODUCT PORTFOLIO
20.28.5 RECENT DEVELOPMENTS
20.29 ASTELLAS PHARMA INC.
20.29.1 COMPANY OVERVIEW
20.29.2 REVENUE ANALYSIS
20.29.3 GEOGRAPHIC PRESENCE
20.29.4 PRODUCT PORTFOLIO
20.29.5 RECENT DEVELOPMENTS
20.3 QUIDEL CORPORATION
20.30.1 COMPANY OVERVIEW
20.30.2 REVENUE ANALYSIS
20.30.3 GEOGRAPHIC PRESENCE
20.30.4 PRODUCT PORTFOLIO
20.30.5 RECENT DEVELOPEMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
21 CONCLUSION
22 QUESTIONNAIRE
23 ABOUT DATA BRIDGE MARKET RESEARCH
